Skip to main content
. 2017 May 4;8(35):59986–59990. doi: 10.18632/oncotarget.17607

Figure 2.

Figure 2

A. Thoracic CT scan of primary lesion before treatment with CBCDA + VP -16, B. Response after 3 cycles of CBCDA + VP -16 and C. progression after 5 cycles of CBCDA + VP -16. D. Liver metastases before treatment with CBCDA + VP -16, E. complete response after 3 cycles and F. persistence of complete response after 5 cycles of CBCDA + VP -16.